Skip to main content
SpringerLink
Log in

Pantoprazole, a Proton Pump Inhibitor, Delays Fracture Healing in Mice

  • Original Research
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

Proton pump inhibitors (PPIs), which are widely used in the treatment of dyspeptic problems, have been shown to reduce osteoclast activity. There is no information, however, on whether PPIs affect fracture healing. We therefore studied the effect of the PPI pantoprazole on callus formation and biomechanics during fracture repair. Bone healing was analyzed in a murine fracture model using radiological, biomechanical, histomorphometric, and protein biochemical analyses at 2 and 5 weeks after fracture. Twenty-one mice received 100 mg/kg body weight pantoprazole i.p. daily. Controls (n = 21) received equivalent amounts of vehicle. In pantoprazole-treated animals biomechanical analysis revealed a significantly reduced bending stiffness at 5 weeks after fracture compared to controls. This was associated with a significantly lower amount of bony tissue within the callus and higher amounts of cartilaginous and fibrous tissue. Western blot analysis showed reduced expression of the bone formation markers bone morphogenetic protein (BMP)-2, BMP-4, and cysteine-rich protein (CYR61). In addition, significantly lower expression of proliferating cell nuclear antigen indicated reduced cell proliferation after pantoprazole treatment. Of interest, the reduced expression of bone formation markers was associated with a significantly diminished expression of RANKL, indicating osteoclast inhibition. Pantoprazole delays fracture healing by affecting both bone formation and bone remodeling.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ferron GM, McKeand W, Mayer PR (2001) Pharmacodynamic modeling of pantoprazole’s irreversible effect on gastric acid secretion in humans and rats. J Clin Pharmacol 41:149–156

    Article  PubMed  CAS  Google Scholar 

  2. Lindberg P, Nordberg P, Alminger T et al (1986) The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem 29:1327–1329

    Article  PubMed  CAS  Google Scholar 

  3. Graziani G, Como G, Badalamenti S et al (1995) Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant 10:1376–1380

    PubMed  CAS  Google Scholar 

  4. O’Connell MB, Madden DM, Murray AM et al (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778–781

    Article  PubMed  Google Scholar 

  5. Targownik LE, Lix LM, Metge CJ et al (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319–326

    Article  PubMed  Google Scholar 

  6. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2953

    Article  PubMed  CAS  Google Scholar 

  7. Yu EW, Blackwell T, Ensrud KE et al (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251–259

    Article  PubMed  CAS  Google Scholar 

  8. Tucker KL, Hannan MT, Qiao N et al (2005) Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res 20:152–158

    Article  PubMed  CAS  Google Scholar 

  9. Farina C, Gagliardi S (2002) Selective inhibition of osteoclast vacuolar H+-ATPase. Curr Pharm Des 8:2033–2048

    Article  PubMed  CAS  Google Scholar 

  10. Tuukkanen J, Väänänen HK (1986) Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 38:123–125

    Article  PubMed  CAS  Google Scholar 

  11. Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+,K+-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21–25

    Article  PubMed  CAS  Google Scholar 

  12. Visentin L, Dodds RA, Valente M et al (2000) A selective inhibitor of the osteoclastic V-H+-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest 106:309–318

    Article  PubMed  CAS  Google Scholar 

  13. Bilic I, Zoricic I, Anic T et al (2001) Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice. Life Sci 68:1905–1912

    Article  PubMed  CAS  Google Scholar 

  14. Masubuchi N, Hakusui H, Okazaki O (1997) Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors. Drug Metab Dispos 25:584–589

    PubMed  CAS  Google Scholar 

  15. Holstein JH, Matthys R, Histing T et al (2008) Development of a stable closed femoral fracture model in mice. J Surg Res 153:71–75

    Article  PubMed  Google Scholar 

  16. Goldberg VM, Powell A, Shaffer JW et al (1985) Bone grafting: role of histocompatibility in transplantation. J Orthop Res 3:389–404

    Article  PubMed  CAS  Google Scholar 

  17. Histing T, Holstein JH, Garcia P et al (2009) Ex vivo analysis of rotational stiffness of different osteosynthesis techniques in mouse femur fracture. J Orthop Res 27:1152–1156

    Article  PubMed  Google Scholar 

  18. Gerstenfeld LC, Wronski TJ, Hollinger JO, Einhorn TA (2005) Application of histomorphometric methods to the study of bone repair. J Bone Miner Res 20:1715–1722

    Article  PubMed  Google Scholar 

  19. Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884

    Article  PubMed  CAS  Google Scholar 

  20. Zaidi M (1990) Modularity of osteoclast behaviour and “mode-specific” inhibition of osteoclast function. Biosci Rep 10:547–556

    Article  PubMed  CAS  Google Scholar 

  21. Sheraly AR, Lickorish D, Sarraf F, Davies JE (2009) Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv 6:192–198

    Article  PubMed  CAS  Google Scholar 

  22. Karsdal MA, Henriksen K, Sørensen MG et al (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467–476

    Article  PubMed  CAS  Google Scholar 

  23. Hyun JJ, Chun HJ, Keum B et al (2010) Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. Int J Mol Med 26:877–883

    PubMed  CAS  Google Scholar 

  24. Gerstenfeld LC, Sacks DJ, Pelis M et al (2009) Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 24:196–208

    Article  PubMed  CAS  Google Scholar 

  25. Marsell R, Einhorn TA (2009) The role of endogenous bone morphogenetic proteins in normal skeletal repair. Injury 40:4–7

    Article  Google Scholar 

  26. Tsuji K, Bandyopadhyay A, Harfe BD et al (2006) BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 38:1424–1429

    Article  PubMed  CAS  Google Scholar 

  27. Devlin RD, Du Z, Pereira RC et al (2003) Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 144:1972–1978

    Article  PubMed  CAS  Google Scholar 

  28. Schütze N, Lechner A, Groll C et al (1998) The human analog of murine cystein rich protein 61 is a 1alpha,25-dihydroxyvitamin D3 responsive immediate early gene in human fetal osteoblasts: regulation by cytokines, growth factors, and serum. Endocrinology 139:1761–1770

    Article  PubMed  Google Scholar 

  29. Si W, Kang Q, Luu HH et al (2006) CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol 26:2955–2964

    Article  PubMed  CAS  Google Scholar 

  30. Su JL, Chiou J, Tang CH et al (2010) CYR61 regulates BMP-2-dependent osteoblast differentiation through the αvβ3 integrin/integrin-linked kinase/ERK pathway. J Biol Chem 285:31325–31336

    Article  PubMed  CAS  Google Scholar 

  31. Hadjiargyrou M, Ahrens W, Rubin CT (2000) Temporal expression of the chondrogenic and angiogenic growth factor CYR61 during fracture repair. J Bone Miner Res 15:1014–1023

    Article  PubMed  CAS  Google Scholar 

  32. Crockett JC, Schütze N, Tosh D et al (2007) The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5. Endocrinology 48:5761–5768

    Article  Google Scholar 

  33. Schütze N, Kunzi-Rapp K, Wagemanns R et al (2005) Expression, purification, and functional testing of recombinant CYR61/CCN1. Protein Expr Purif 42:219–225

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have stated that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Trauma, Hand, and Reconstructive Surgery, University of Saarland, 66421, Homburg/Saar, Germany

    T. Histing, D. Stenger, W. Metzger, P. Garcia, J. H. Holstein, M. Klein & T. Pohlemann

  2. CRC Homburg (Collaborative Research Center), AO Foundation, Davos, Switzerland

    T. Histing, D. Stenger, C. Scheuer, W. Metzger, P. Garcia, J. H. Holstein, M. Klein, T. Pohlemann & M. D. Menger

  3. Institute for Clinical & Experimental Surgery, University of Saarland, 66421, Homburg/Saar, Germany

    C. Scheuer & M. D. Menger

Authors
  1. T. Histing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Stenger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Scheuer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Metzger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. H. Holstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T. Pohlemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. D. Menger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Histing.

Additional information

The first two authors contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Histing, T., Stenger, D., Scheuer, C. et al. Pantoprazole, a Proton Pump Inhibitor, Delays Fracture Healing in Mice. Calcif Tissue Int 90, 507–514 (2012). https://doi.org/10.1007/s00223-012-9601-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-012-9601-x

Keywords

Search

Navigation